Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Teva Investigational Site 145
-
Phoenix, Arizona, United States, 85032
- Teva Investigational Site 130
-
Scottsdale, Arizona, United States, 85259
- Teva Investigational Site 117
-
-
California
-
Anaheim, California, United States, 92801
- Teva Investigational Site 161
-
Fullerton, California, United States, 92835
- Teva Investigational Site 116
-
Long Beach, California, United States, 90806
- Teva Investigational Site 119
-
Oceanside, California, United States, 92056
- Teva Investigational Site 146
-
San Francisco, California, United States, 94109
- Teva Investigational Site 113
-
Stanford, California, United States, 94305
- Teva Investigational Site 108
-
Walnut Creek, California, United States, 94598
- Teva Investigational Site 112
-
-
Colorado
-
Boulder, Colorado, United States, 80304
- Teva Investigational Site 132
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
- Teva Investigational Site 162
-
-
Florida
-
DeLand, Florida, United States, 32720
- Teva Investigational Site 143
-
Hialeah, Florida, United States, 33012
- Teva Investigational Site 137
-
Jacksonville, Florida, United States, 32216
- Teva Investigational Site 101
-
Jacksonville, Florida, United States, 32256
- Teva Investigational Site 166
-
Maitland, Florida, United States, 32751
- Teva Investigational Site 129
-
Orlando, Florida, United States, 32801
- Teva Investigational Site 167
-
Ormond Beach, Florida, United States, 32174
- Teva Investigational Site 139
-
Port Orange, Florida, United States, 32127
- Teva Investigational Site 140
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Teva Investigational Site 149
-
Decatur, Georgia, United States, 30030
- Teva Investigational Site 164
-
Douglasville, Georgia, United States, 30134
- Teva Investigational Site 134
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Teva Investigational Site 125
-
-
Kansas
-
Lenexa, Kansas, United States, 66214
- Teva Investigational Site 133
-
-
Massachusetts
-
Brockton, Massachusetts, United States, 02301
- Teva Investigational Site 135
-
New Bedford, Massachusetts, United States, 02740
- Teva Investigational Site 124
-
Springfield, Massachusetts, United States, 01104
- Teva Investigational Site 151
-
Watertown, Massachusetts, United States, 02472
- Teva Investigational Site 109
-
Worcester, Massachusetts, United States, 01605
- Teva Investigational Site 115
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- Teva Investigational Site 110
-
Kalamazoo, Michigan, United States, 49009
- Teva Investigational Site 114
-
-
Minnesota
-
Golden Valley, Minnesota, United States, 55422
- Teva Investigational Site 150
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- Teva Investigational Site 152
-
Saint Louis, Missouri, United States, 63141
- Teva Investigational Site 104
-
Springfield, Missouri, United States, 65807
- Teva Investigational Site 107
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Teva Investigational Site 148
-
-
New York
-
Bronx, New York, United States, 10461
- Teva Investigational Site 105
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27405-6962
- Teva Investigational Site 131
-
Raleigh, North Carolina, United States, 27607
- Teva Investigational Site 118
-
Winston-Salem, North Carolina, United States, 27103
- Teva Investigational Site 168
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Teva Investigational Site 122
-
Cincinnati, Ohio, United States, 45227
- Teva Investigational Site 141
-
Cincinnati, Ohio, United States, 45229-3039
- Teva Investigational Site 142
-
Cleveland, Ohio, United States, 44195
- Teva Investigational Site 155
-
Columbus, Ohio, United States, 43221
- Teva Investigational Site 102
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Teva Investigational Site 127
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Teva Investigational Site 111
-
-
South Carolina
-
Goose Creek, South Carolina, United States, 29445
- Teva Investigational Site 120
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Teva Investigational Site 153
-
Memphis, Tennessee, United States, 38119
- Teva Investigational Site 126
-
Nashville, Tennessee, United States, 37203
- Teva Investigational Site 154
-
-
Texas
-
Arlington, Texas, United States, 76012
- Teva Investigational Site 128
-
Austin, Texas, United States, 78731
- Teva Investigational Site 121
-
Austin, Texas, United States, 78745
- Teva Investigational Site 136
-
-
Virginia
-
Charlottesville, Virginia, United States, 22911
- Teva Investigational Site 123
-
Roanoke, Virginia, United States, 24018
- Teva Investigational Site 144
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females aged 18 to 65 years of age.
- A signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments.
- Chronic migraine meeting the diagnostic criteria listed in the International Classification of Headache Disorders (ICHD-III beta version, 2013)
- Body Mass Index (BMI) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and 120 kg inclusive.
- Demonstrated compliance with the electronic headache diary during the run-in period headache data on a minimum of 22/28 days (80% diary compliance)
Exclusion Criteria:
- Onset of chronic migraine after the age of 50 years.
- Subject has received onabotulinum toxin A for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 6 months prior to study entry.
- Subject is using medications containing opioids (including codeine) or barbiturates (including Fiorinal®, Fioricet®, or any other combination containing butalbital) on more than 4 days per month for the treatment of migraine or for any other reason.
- Failed > 2 medication categories or > 3 preventive medications (within two medication categories) due to lack of efficacy for prophylactic treatment of episodic or chronic migraine after an adequate therapeutic trial
- Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LBR-101 High Dose
Subcutaneous High Dose LBR-101 Administered Monthly x 3
|
Subcutaneously Administered LBR-101 Monthly x 3
Other Names:
|
|
Experimental: LBR-101 Low Dose
Subcutaneous Low Dose LBR-101 Administered Monthly x 3
|
Subcutaneously Administered LBR-101 Monthly x 3
Other Names:
|
|
Placebo Comparator: Placebo
Subcutaneous Placebo Administered Monthly x 3
|
Subcutaneously Administered Placebo (Vehicle) Monthly x 3
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With at Least One Adverse Event
Time Frame: Baseline to week 12
|
An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug.
Relationship of AE to treatment was determined by the Investigator.
Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent the previously listed serious outcomes.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
|
Baseline to week 12
|
|
Mean Change From Baseline in the Number of Monthly Cumulative Headache Hours of Any Severity on Headache Days Relative to the 28-day Post-treatment Period Ending With Week 12
Time Frame: Baseline to week 12
|
A headache day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache of any severity or the participant used acute migraine medication (triptans and ergot compounds) to treat a headache.
This calculation was defined as the change from baseline in the number of hours with headache of any severity during the 28-day post treatment period ending at week 12. Headache severity was rated daily by the participant as either no pain, mild, moderate, or severe.
|
Baseline to week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Change From Baseline in the Number of Headache Days of at Least Moderate Severity Relative to the 28-day Post-treatment Period Ending With Week 12
Time Frame: Baseline to week 12
|
A headache day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache of any severity or the participant used acute migraine medication (triptans and ergot compounds) to treat a headache.
This calculation was defined as the change from baseline in the number of headache days of at least moderate severity during the 28-day post treatment period ending at week 12. Headache severity was rated daily by the participant as either no pain, mild, moderate, or severe.
|
Baseline to week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology. 2018 Sep 18;91(12):e1152-e1165. doi: 10.1212/01.wnl.0000544321.19316.40. Epub 2018 Aug 17.
- Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia. 2019 Jan;39(1):52-60. doi: 10.1177/0333102418772585. Epub 2018 May 3.
- Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. Headache. 2017 Oct;57(9):1375-1384. doi: 10.1111/head.13156. Epub 2017 Sep 1.
- Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LBR-101-021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.